CIDP (chronic inflammatory demyelinating polyneuropathy) trials in United Kingdom

In United Kingdom 7 Also abroad 43

7 of 7 trials · From ClinicalTrials.gov, checked 15 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Where
Bristol, Glasgow, Salford, Southampton
Age
18 years and over
People
162 worldwide
Run by
Immunovant Sciences GmbH
See details and how to joinNCT07032662 · EU 2024-517614-14-00
Phase 3Taking people
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
Where
Canterbury, London, Nottingham, Salford
Age
18 years and over
People
160 worldwide
Run by
argenx
See details and how to joinNCT07091630 · EU 2025-520805-10-00
Phase 2/3Completed
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Where
Birmingham, Devon, Glasgow, London, Sheffield
Age
18 years and over
People
201 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05327114 · EU 2023-508425-28-00
Phase 3Taking people
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
Where
Leeds, London, Salford
Age
18 years and over
People
218 worldwide
Run by
argenx
See details and how to joinNCT06920004 · EU 2024-520097-36-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
Where
Manchester, Oxford
Age
18 years to 75 years
People
256 worldwide
Run by
Dianthus Therapeutics
See details and how to joinNCT06858579
Phase 3Enrolling by invitation
Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
Where
Oxford
Age
18 years and over
People
300 worldwide
Run by
Sanofi
See details and how to joinNCT06859099 · EU 2024-517032-22-00
Phase 3Taking people
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Where
Inverness, London, Oxford
Age
18 years and over
People
160 worldwide
Run by
Sanofi
See details and how to joinNCT06290141 · EU 2023-508338-33-00